Rein Therapeutics Q2 FY26 net loss narrows to $6.38 million; operating loss improves 11.57% to $6.08 million - RNTX News | RalliesRein Therapeutics Q2 FY26 net loss narrows to $6.38 million; operating loss improves 11.57% to $6.08 million
R
RNTX• Cash position and clinical timeline
- Cash, cash equivalents and investments totaled USD 43.6 million at June 30, 2026; runway expected into Q1 2028.
- Interim Phase 2 RENEW data is targeted in Q4 2026.
Research and development spending declines
- Research and development expense dropped to USD 3.64 million from USD 4.29 million, due to timing of third-party CRO services.
- Other expense swung to USD 299,000 from income of USD 49,000, driven by discount amortization on promissory notes.
Quarterly loss and operating expenses narrow
- Rein Therapeutics posted a net loss of USD 6.38 million for the quarter ended June 30, 2026, narrowing from USD 6.82 million.
- Operating loss narrowed to USD 6.08 million from USD 6.87 million as total operating expenses fell to .
USD 6.08 million
ORI
•
